Abstract
In an open study the concentrations of azithromycin in plasma, urine, peritoneal fluid and gynaecological tissue in 20 patients undergoing elective gynaecological surgery were compared. Patients were allocated to one of four groups and all patients received a single 500 mg oral dose of azithromycin prior to surgery. In Group I, the dose was administered 24 h before surgery. In Groups II, III and IV it was administered 48, 72 and 96 h, respectively, prior to surgery. A total of 19 patients completed the study; one patient had peri-operative complications and did not proceed to surgery. High concentrations of azithromycin were found in gynaecological tissue up to 96 h after administration. The mean maximum observed concentration 24 h after administration was 1.44 ± 0.22 µg/g. Using all data, the depletion rate constant was 0.0104 h−1, equivalent to a half-life of approximately 67 h. The mean concentration of drug in peritoneal fluid was approximately 9 % of the mean concentration in gynaecological tissue. Tissue and peritoneal fluid azithromycin concentrations were much higher than plasma levels at the time of surgery. Detectable plasma levels were only found in four patients from Groups I and II. Six percent of the total dose was excreted in the urine during the seven-day period after drug administration. The single dose of azithromycin was well tolerated by all the patients in this study and no treatment-related side effects or laboratory test abnormalities were seen. It is concluded that a single 500 mg oral dose of azithromycin produces high and sustained levels in gynaecological tissue up to 96 h after administration.
Similar content being viewed by others
References
Washington JA, Wilson WR: Erythromycin: a microbial and clinical perspective after 30 years of clinical use. Mayo Clinic Proceedings 1985, 60: 189–203.
Wilson JT, van Boxtel CJ: Pharmacokinetics of erythromycin in man. Antibiotics and Chemotherapy 1978, 25: 181–203.
Slaney L, Plummer F, Ronald AR, Degagne P, Hoban D, Brunham RC: In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin againstNeisseria gonorrhoeae, Haemophilus ducreyi andChlamydia trachomatis. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 1–5.
Rylander M, Hallander HO: In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide. CP-62,993 againstMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticum. Scandinavian Journal of Infectious Diseases 1988, 53, Supplement A: 12–17.
Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC: Azithromycin in the treatment of sexually transmitted disease. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 109–114.
Fiese EF, Steffen SH: Comparison of the acid stability of azithromycin and erythromycin A. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 39–47.
Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 73–82.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krohn, K. Gynaecological tissue levels of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 10, 864–868 (1991). https://doi.org/10.1007/BF01975844
Issue Date:
DOI: https://doi.org/10.1007/BF01975844